# Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation

> **NCT02932488** · PHASE1 · TERMINATED · sponsor: **Gitte Moos Knudsen** · enrollment: 17 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Sumatriptan

## Key facts

- **NCT ID:** NCT02932488
- **Lead sponsor:** Gitte Moos Knudsen
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Pilot study with sumatriptan found no significant changes in the primary outcome parameter (change in CBF)
- **Last updated:** 2019-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02932488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02932488, "Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02932488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*